High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy
高分辨率血浆代谢组学分析可识别结核病生物标志物和治疗反应
基本信息
- 批准号:9432482
- 负责人:
- 金额:$ 20.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-14 至 2020-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgeAmino AcidsAnti-Retroviral AgentsAntitubercular AgentsApplications GrantsBiologicalBiological MarkersBloodCaucasiansCell WallClinical MarkersCommunicable DiseasesCountryCoupledDataDetectionDevelopmentDiagnosisDiagnostic testsDiglyceridesDiseaseDrug-sensitiveFunctional disorderFutureGlycolipidsGoalsHIVHIV SeropositivityHealthHouseholdHumanHybridsIndividualIonsKnowledgeLeadLinkMetabolicMetabolic PathwayMethodsMultidrug-Resistant TuberculosisMycobacterium tuberculosisOutcomePIM1 genePathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPhosphatidylglycerolsPhosphatidylinositolsPilot ProjectsPlasmaPulmonary TuberculosisRecoveryRecovery of FunctionRegulationResolutionSamplingSchemeSensitivity and SpecificitySeriesSouth AfricaSouth AfricanSputumTestingTimeTrehaloseTuberculosisValidationattributable mortalitybasecell envelopeco-infectioncohortdesigndisorder controlimprovedlipid mediatorlipid metabolismmass spectrometermetabolic profilemetabolomicsmortalitymycolatenovelpathogenpoint-of-care diagnosticspotential biomarkerpredictive markerprimary endpointrapid detectionresponsesecondary endpointsexsmall moleculespecific biomarkerstreatment responsetuberculosis drugstuberculosis treatmentultra high resolution
项目摘要
Summary/abstract: Tuberculosis (TB) is the number one infectious disease killer in the world with 1.5 million
deaths attributable to the disease in 2014. A critical knowledge gap exists given the lack of biological
pathways and predictive biomarkers related to TB onset, progression and resolution. An improved diagnostic
test for TB would have a major impact on global control of the disease and reduce mortality. Unfortunately,
there are no validated biomarkers for TB onset, progression and resolution; the development of a TB
biomarker is urgently needed. Current ultra-high-resolution metabolomics (HRM) methods have considerable
promise for the development of TB-associated biomarkers. Several studies have identified distinguishing small
molecule metabolic profiles in blood and other bio samples in individuals with active Mycobacterium
tuberculosis (Mtb)-induced TB disease compared to uninfected controls, but no studies have explored whether
metabolomics is predictive of TB outcomes, Mtb clearance from sputum. Further, all studies to date have used
low-resolution metabolomics methods. Advances in mass spectrometer machine capability, coupled with
recent advanced data extraction/analysis methods has considerably increased the dynamic range of
metabolite detection by HRM in biologic samples, which now exceeds 20,000 species (>100,000 ions). Our
HRM processing scheme provides capability to detect very low abundance metabolites, including Mtb cell
envelope glycolipids, and explore regulation of human metabolic pathways. In a pilot study, we successfully
identified 61 plasma metabolites that differentiated adults with active pulmonary TB from household contacts
without TB. Differentiating species included specific Mtb-derived cell wall glycolipids and endogenous lipid
mediator resolvins. Our recent pilot data shows that specific metabolites and human metabolic pathways,
including those involved in drug, amino acid, and lipid metabolism, are associated with the propensity for
sputum Mtb culture clearance over time. The ultimate goal of this exploratory proposal is to obtain novel data
that may lead to the development of new TB biomarkers. We hypothesize that plasma HRM analysis can: 1)
predict the propensity for successful anti-TB treatment by identifying Mtb-derived and endogenous metabolites
(biomarkers) and human metabolic pathways (pathophysiology) associated with sputum Mtb clearance; and 2)
successfully differentiate patients with active TB from controls without latent TB infection (LTBI) or TB disease.
To test these hypotheses, we propose the following Specific Aims in this exploratory R21 project:
Specific Aim 1: To determine whether plasma HRM analysis can identify Mtb-derived and endogenous
metabolites that predict clearance of Mtb from sputum (change from positive to negative culture).
Specific Aim 2: To determine whether plasma HRM analysis can differentiate adults with drug-
sensitive or MDR-TB ± HIV co-infection from asymptomatic controls without LTBI.
摘要/摘要:结核病是世界头号传染病杀手,有150万人
2014年可归因于该疾病的死亡。由于缺乏生物学知识,存在着严重的知识鸿沟
与结核病发病、进展和消退相关的途径和预测性生物标记物。一种改进的诊断
结核病检测将对全球疾病控制和降低死亡率产生重大影响。不幸的是,
目前尚无有效的生物标记物可用于结核病的发病、进展和消退;
迫切需要生物标记物。目前的超高分辨率代谢组学(HRM)方法有相当大的
为结核病相关生物标志物的开发提供了希望。几项研究已经确定了区别于小的
活动性分枝杆菌携带者血液和其他生物样本中的分子代谢特征
结核病(Mtb)引起的结核病与未感染的对照组相比,但没有研究探索是否
代谢组学可以预测结核转归、结核分枝杆菌从痰中清除。此外,到目前为止的所有研究都使用了
低分辨率代谢组学方法。质谱计机器能力的进步,加上
最近先进的数据提取/分析方法大大增加了动态范围
HRM在生物样本中检测代谢物,目前已超过20,000种(>;100,000离子)。我们的
HRM处理方案提供了检测极低丰度代谢物的能力,包括结核分枝杆菌细胞
包膜糖脂,并探索人类代谢途径的调节。在一项初步研究中,我们成功地
鉴定61种血浆代谢物,区分成人活动性肺结核和家庭接触者
没有结核病。分化的物种包括特定的结核分枝杆菌衍生的细胞壁糖脂和内源性脂肪
调解人解决方案。我们最近的试验数据显示,特定的代谢物和人类的代谢途径,
包括那些涉及药物、氨基酸和脂类代谢的物质,都与
痰结核分枝杆菌培养随时间推移而清除。这一探索性建议的最终目标是获得新的数据
这可能会导致新的结核病生物标记物的开发。我们假设血浆HRM分析可以:1)
通过鉴定结核分枝杆菌衍生和内源性代谢物预测成功抗结核治疗的倾向
(生物标志物)和与痰结核分枝杆菌清除有关的人体代谢途径(病理生理学);以及2)
成功地将活动性结核病患者与没有潜在结核病感染(LTBI)或结核病疾病的对照组区分开来。
为了验证这些假设,我们在这个探索性的R21项目中提出了以下具体目标:
具体目标1:确定血浆HRM分析是否可以识别结核分枝杆菌来源和内源性
预测结核分枝杆菌从痰中清除的代谢物(从阳性培养变为阴性培养)。
具体目标2:确定血浆HRM分析是否可以区分成人与药物
来自无LTBI的无症状对照的敏感或MDR-TB±HIV混合感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dean Paul Jones其他文献
Dean Paul Jones的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dean Paul Jones', 18)}}的其他基金
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
10201601 - 财政年份:2018
- 资助金额:
$ 20.17万 - 项目类别:
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
9769022 - 财政年份:2018
- 资助金额:
$ 20.17万 - 项目类别:
Mega-scale Identification tools for xenobiotic metabolism
外源代谢的大规模鉴定工具
- 批准号:
9981744 - 财政年份:2018
- 资助金额:
$ 20.17万 - 项目类别:
High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy
高分辨率血浆代谢组学分析可识别结核病生物标志物和治疗反应
- 批准号:
9300433 - 财政年份:2017
- 资助金额:
$ 20.17万 - 项目类别:
Georgia Comprehensive Metabolomics and Proteomics Unit for MoTrPAC
佐治亚州 MoTrPAC 综合代谢组学和蛋白质组学单位
- 批准号:
9246760 - 财政年份:2016
- 资助金额:
$ 20.17万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8625332 - 财政年份:2012
- 资助金额:
$ 20.17万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8286494 - 财政年份:2012
- 资助金额:
$ 20.17万 - 项目类别:
Metabolomics of subclinical and clinical cardiovascular disease
亚临床和临床心血管疾病的代谢组学
- 批准号:
8463610 - 财政年份:2012
- 资助金额:
$ 20.17万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 20.17万 - 项目类别:
Research Grant